초록 ▼

Pharmaceutical compositions of matter adapted for intravaginal administration comprise a biologically active polypeptide, an absorption promoter, such as an anionic and/or nonionic surfactant or a nonionic surfactant and an aliphatic carboxylic acid, optionally an animal and/or vegetable protein and

Pharmaceutical compositions of matter adapted for intravaginal administration comprise a biologically active polypeptide, an absorption promoter, such as an anionic and/or nonionic surfactant or a nonionic surfactant and an aliphatic carboxylic acid, optionally an animal and/or vegetable protein and a nontoxic pharmaceutically acceptable carrier or diluent therefor, in a formulation suitable for intravaginal administration. Preferred compositions comprise calcitonin as the biologically active polypeptide. Preferred absorption promoters are anionic surfactants, e.g., sodium lauryl sulfate, and the combination absorption promoter of a nonionic surfactant and a medium chain aliphatic carboxylic acid or its salt, e.g. polyoxyethylenealkylphenylether and a medium chain aliphatic carboxylic acid.

대표청구항 ▼

[ What is claimed is:] [1.] An improved method for administering calcitonin or an analog thereof to a mammal in need of such treatment, comprising intravaginally administering a pharmaceutical composition comprising a stable biologically active polypeptide selected from the group consisting of a cal

[ What is claimed is:] [1.] An improved method for administering calcitonin or an analog thereof to a mammal in need of such treatment, comprising intravaginally administering a pharmaceutical composition comprising a stable biologically active polypeptide selected from the group consisting of a calcitonin and calcitonin analogs, in an amount sufficient to elicit a pharmacological effect when administered intravaginally; an absorption promoter consisting essentially of a combination of nonionic surfactant and a saturated medium chain aliphatic carboxylic acid having from 6 to 16 carbon atoms or alkali salt thereof, the total concentration of absorption promoter in the composition being between 0.01 and 5 w/v%, said concentration being sufficient to enhance absorption of the polypeptide through the vaginal mucosa; and a nontoxic pharmaceutically acceptable carrier therefor, in a formulation suitable for intravaginal administration.